Stocks to Watch: Nurix Therapeutics, Personalis, WK Kellogg

Dow Jones

Jul 10

By Katherine Hamilton

Nurix Therapeutics reported revenue in its fiscal second quarter more than tripled to $44.1 million, far surpassing analysts' expectations. Shares climbed 11%, to $14.59, after hours Wednesday.

Personalis expanded its work with Tempus AI on a detection test to include colorectal cancer among the diseases the test can detect. Shares rose 9%, to $7.80, in after-hours trading.

WK Kellogg could be acquired for $3 billion by candy-maker Ferrero, the Wall Street Journal reported. Shares soared 55%, to $27.05, after the market closed.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

July 09, 2025 19:09 ET (23:09 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2550766947"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550766947\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550766947?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-10 07:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550766947","market":"sh","top_or_hot":-1,"title":"Stocks to Watch: Nurix Therapeutics, Personalis, WK Kellogg","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine <a href=\"https://laohu8.com/S/HBK\">Hamilton</a> \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> reported revenue in its fiscal second quarter more than tripled to $44.1 million, far surpassing analysts' expectations. Shares climbed 11%, to $14.59, after hours Wednesday. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/PSNL\">Personalis</a> expanded its work with <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> on a detection test to include colorectal cancer among the diseases the test can detect. Shares rose 9%, to $7.80, in after-hours trading. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/KLG\">WK Kellogg</a> could be acquired for $3 billion by candy-maker Ferrero, the Wall Street Journal reported. Shares soared 55%, to $27.05, after the market closed. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2025 19:09 ET (23:09 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Nurix Therapeutics, Personalis, WK Kellogg</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Nurix Therapeutics, Personalis, WK Kellogg\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-10 07:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine <a href=\"https://laohu8.com/S/HBK\">Hamilton</a> \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> reported revenue in its fiscal second quarter more than tripled to $44.1 million, far surpassing analysts' expectations. Shares climbed 11%, to $14.59, after hours Wednesday. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/PSNL\">Personalis</a> expanded its work with <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> on a detection test to include colorectal cancer among the diseases the test can detect. Shares rose 9%, to $7.80, in after-hours trading. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/KLG\">WK Kellogg</a> could be acquired for $3 billion by candy-maker Ferrero, the Wall Street Journal reported. Shares soared 55%, to $27.05, after the market closed. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2025 19:09 ET (23:09 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0757428866.USD","symbol_name":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550766947","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550766947","pubTimestamp":1752102540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Nurix Therapeutics reported revenue in its fiscal second quarter more than tripled to $44.1 million, far surpassing analysts' expectations. Shares climbed 11%, to $14.59, after hours Wednesday.Personalis expanded its work with Tempus AI on a detection test to include colorectal cancer among the diseases the test can detect. Shares rose 9%, to $7.80, in after-hours trading.WK Kellogg could be acquired for $3 billion by candy-maker Ferrero, the Wall Street Journal reported. Shares soared 55%, to $27.05, after the market closed.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","BK4023":"应用软件","BK4139":"生物科技","WK":"Workiva","BK4212":"包装食品与肉类","PSNL":"Personalis","BK4121":"生命科学工具和服务","KLG":"WK Kellogg Co.","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","NRIX":"Nurix Therapeutics","LU0566484027.USD":"安本美国小盘成长股"},"translate_title":"值得关注的股票：Nurix Therapeutics、Personalis、WK Kellogg","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WK":1,"NRIX":1,"KLG":0.9,"PSNL":1},"content_text":"By Katherine Hamilton\n\n\n \n\n\nNurix Therapeutics reported revenue in its fiscal second quarter more than tripled to $44.1 million, far surpassing analysts' expectations. Shares climbed 11%, to $14.59, after hours Wednesday. \n\n\nPersonalis expanded its work with Tempus AI on a detection test to include colorectal cancer among the diseases the test can detect. Shares rose 9%, to $7.80, in after-hours trading. \n\n\nWK Kellogg could be acquired for $3 billion by candy-maker Ferrero, the Wall Street Journal reported. Shares soared 55%, to $27.05, after the market closed. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 09, 2025 19:09 ET (23:09 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}